Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01091246 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children
A Phase 3 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,312
- Enrollment target
NCT01091246 is a Phase 3 study that has completed, run by MedImmune. The registered enrollment target is 2,312 participants.
The verdict
NCT01091246, a Phase 3 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,312 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate the immunologic noninferiority of Q/LAIV to FluMist in children 2 to 17 years of age.
Interventions
- BIOLOGICAL Q/LAIV (MEDI3250)
- BIOLOGICAL FluMist/B/Yamagata
- BIOLOGICAL FluMist/B/Victoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,312 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01091246
The ClinicalTrials.gov registry entry for NCT01091246 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,312 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Q/LAIV (MEDI3250) is the first listed.
NCT01091246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01091246 about?
NCT01091246 is a clinical study titled "A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children". The primary objective of this study is to demonstrate the immunologic noninferiority of Q/LAIV to FluMist in children 2 to 17 years of age.
What is the current status of trial NCT01091246?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,312 participants. The study started on 2010-03. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01091246?
The interventions under investigation include: Q/LAIV (MEDI3250) (BIOLOGICAL), FluMist/B/Yamagata (BIOLOGICAL), FluMist/B/Victoria (BIOLOGICAL).
Who is sponsoring clinical trial NCT01091246?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.